Chapter 54: Adult Cardiovascular Medications

Medications affecting coagulation represent a major category, including anticoagulants such as heparin sodium and warfarin sodium that inhibit clot formation through different pathways, with heparin requiring activated partial thromboplastin time monitoring and warfarin requiring international normalized ratio assessment. Thrombolytic agents operate distinctly by actively dissolving existing clots through plasminogen activation, making them essential in acute myocardial infarction management when administered within narrow treatment windows. Antiplatelet medications further reduce thrombotic risk by inhibiting platelet aggregation. For heart failure management, positive inotropic agents including dobutamine, dopamine, and milrinone enhance myocardial contractility and cardiac output, while cardiac glycosides like digoxin provide dual benefits through increased contractile force and reduced heart rate, though requiring careful monitoring due to narrow therapeutic ranges and potential toxicity manifesting as gastrointestinal and visual symptoms. Antihypertensive therapy encompasses diverse mechanisms including diuretics that work at different nephron sites with distinct electrolyte implications, adrenergic blockers that reduce sympathetic stimulation while presenting specific contraindications and adverse effects, and renin-angiotensin system inhibitors that prevent vasoconstriction through enzyme or receptor blockade. Antianginal and vasodilator medications reduce myocardial oxygen demand and lower blood pressure acutely, with nitrates requiring specific storage protocols and administration schedules. The chapter also addresses antidysrhythmic agents organized by their electrophysiological properties and antilipemic medications that modify lipid metabolism, each carrying important safety considerations and patient education requirements. Understanding these medication classes, their appropriate monitoring parameters, patient responses, and nursing implications is essential for optimizing cardiovascular outcomes and preventing medication-related complications.